CN Patent

CN1345240A — 用替莫唑胺改善癌症治疗

Assigned to Merck Sharp and Dohme LLC · Expires 2002-04-17 · 24y expired

What this patent protects

本发明提供一种治疗癌症病人的方法,该方法给予所述病人至少两个周期的给药周期剂量表的替莫唑胺,其中各周期包括5－25天的给药期,在此给药期内每天给予40－150mg/m 2 /天剂量的替莫唑胺,接着是5－14天的休息期,在此休息期内不给予替莫唑胺。本发明也提供一种给予替莫唑胺的药盒,该药盒具有按照上述周期给药剂量表给予替莫唑胺的打印说明书和至少一个周期的剂量单位形式的替莫唑胺,其中各剂量单位含有5－250mg替莫唑胺和可药用载体。

USPTO Abstract

本发明提供一种治疗癌症病人的方法,该方法给予所述病人至少两个周期的给药周期剂量表的替莫唑胺,其中各周期包括5－25天的给药期,在此给药期内每天给予40－150mg/m 2 /天剂量的替莫唑胺,接着是5－14天的休息期,在此休息期内不给予替莫唑胺。本发明也提供一种给予替莫唑胺的药盒,该药盒具有按照上述周期给药剂量表给予替莫唑胺的打印说明书和至少一个周期的剂量单位形式的替莫唑胺,其中各剂量单位含有5－250mg替莫唑胺和可药用载体。

Drugs covered by this patent

Patent Metadata

Patent number
CN1345240A
Jurisdiction
CN
Classification
—
Expires
2002-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.